BioXcel Therapeutics Enters Material Definitive Agreement
Ticker: BTAI · Form: 8-K · Filed: Mar 4, 2025 · CIK: 1720893
Sentiment: neutral
Topics: material-agreement, definitive-agreement
Related Tickers: BTAI
TL;DR
BioXcel Therapeutics signed a big deal on March 3rd, details TBD.
AI Summary
On March 3, 2025, BioXcel Therapeutics, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement or any associated dollar amounts. The company is incorporated in Delaware and its principal executive offices are located at 555 Long Wharf Drive, New Haven, CT 06511.
Why It Matters
This filing indicates a significant new agreement for BioXcel Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The filing reports a material definitive agreement, but lacks specific details, creating uncertainty about its implications.
Key Players & Entities
- BioXcel Therapeutics, Inc. (company) — Registrant
- March 3, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 555 Long Wharf Drive, New Haven, CT 06511 (address) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by BioXcel Therapeutics?
The filing does not specify the nature of the material definitive agreement.
When was the material definitive agreement entered into?
The material definitive agreement was entered into on March 3, 2025.
What is the principal executive office address for BioXcel Therapeutics?
The principal executive office address is 555 Long Wharf Drive, New Haven, CT 06511.
In which state is BioXcel Therapeutics incorporated?
BioXcel Therapeutics, Inc. is incorporated in Delaware.
Does the filing disclose any financial terms or dollar amounts related to the agreement?
No, the filing does not disclose any specific dollar amounts or financial terms related to the agreement.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 4, 2025 regarding BioXcel Therapeutics, Inc. (BTAI).